Future Opportunity: National Cancer Audit Collaborating Centre

Published: 05 Oct 2021

HQIP plans to commission five new national clinical audits to improve care quality and outcomes, and reduce unwarranted variation in the following clinical areas:

  • Metastatic Breast Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Non-Hodgkin Lymphoma
  • Kidney Cancer

All five audit topics will cover care delivered in England and Wales. They will be included under a single contract for a National Cancer Audit Collaborating Centre. A Market Engagement exercise to inform this decision ran between 1 and 14 September 2021. The results have been evaluated and will inform the final specification for the Centre.

The contract will be for three years with potential to extend for an additional two years. The value of the contract is anticipated to be to a maximum of circa £1.5 million per annum excluding VAT.

The timeline for the procurement is awaiting final confirmation. It will run no earlier than the provisional dates listed below:

Procurement timeline (provisional) programme


Provisional dates

Prior Information Notice (PIN) published, HQIP website information updated, and draft specification and Market Engagement Questionnaire available via HQIP’s
e-tendering Portal – Wax Digital
Closed – September 2021
Invitation to Tender (ITT) live to bidders November-December 2021
Outcome confirmed to bidders March/April 2022
Contract start Summer 2022

This opportunity is covered by the Public Contract Regulations (PCR) 2015. The procedure that HQIP will be following will be set out in the Invitation to Tender. The procurement will also be advertised via Finder a Tender and Contracts Finder.